Using adalimumab serum concentration to choose a subsequent biological DMARD in rheumatoid arthritis patients failing adalimumab treatment (ADDORA-switch): study protocol for a fully blinded randomised superiority test-treatment trial

BACKGROUND: A substantial proportion of rheumatoid arthritis (RA) patients discontinues treatment with tumour necrosis factor inhibitors (TNFi) due to inefficacy or intolerance. After the failure of treatment with a TNFi, treatment can be switched to another TNFi or a bDMARD with a different mode of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Wientjes, Maike H. M., Atiqi, Sadaf, Wolbink, Gerrit Jan, Nurmohamed, Michael T., Boers, Maarten, Rispens, Theo, de Vries, Annick, van Vollenhoven, Ronald F., van den Bemt, Bart J. F., den Broeder, Alfons A.
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2021
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC8214249/
https://ncbi.nlm.nih.gov/pubmed/34147123
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-021-05358-7
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados